Key result
Recombinant tissue plasminogen activator (rtPA) successfully treated two cases of acute pulmonary embolism with right-sided thrombus, dramatically improving right ventricular failure within hours.
Why the study?
Does recombinant tissue plasminogen activator (rtPA) improve acute right ventricular failure in patients with severe pulmonary embolism and right-sided thrombi?
Case Report (n=2)
Does recombinant tissue plasminogen activator (rtPA) improve acute right ventricular failure in patients with severe pulmonary embolism and right-sided thrombi?
Recombinant tissue plasminogen activator (rtPA) can successfully treat life-threatening acute right ventricular failure in patients with severe pulmonary embolism and mobile right atrial thrombi.
Suggests potential rtPA benefit in PE with right thrombi and RV failure; hypothesis-generating and should not yet change practice.
Hereby, we report two cases of acute pulmonary embolism with concomitant right-sided thrombus, which were successfully treated using recombinant tissue plasminogen activator (rtPA). These patients had life-threatening acute right ventricular failure, which dramatically improved within hours following thrombolysis. These cases emphasize the clinical utility of rtPA for the treatment of life-threatening pulmonary embolism.
No takes yet. Share an insight, caveat, or question.
Şatıroğlu et al. (2014) conducted a case report in Acute pulmonary embolism with concomitant right-sided thrombus (n=2). Recombinant tissue plasminogen activator (rtPA) was evaluated on Improvement of acute right ventricular failure. Recombinant tissue plasminogen activator (rtPA) successfully treated two cases of acute pulmonary embolism with right-sided thrombus, dramatically improving right ventricular failure within hours.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: